

**Table S1.** Clinical trial protocol

<b>Study Title</b>  A single-centre, open single-arm study where the safety, tolerability and efficacy of subcutaneously administered ILB® will be evaluated in patients with Amyotrophic Lateral Sclerosis	
<b>Study code</b>  TM-105	<b>EudraCT No</b>  2017-005065-47
<b>Study period</b>  Estimated date of first subject enrolled: Q2 2018  Estimated date of last subject completed: Q3 2019	<b>Phase of development</b>  Phase IIa - pilot
<b>Study design and duration</b>  This was a Phase IIa single-centre, open single-arm study in patients with Amyotrophic Lateral Sclerosis.  Eligible subjects were administered weekly doses of 1 mg/kg ILB®. A total of 5 subcutaneous (s.c.) doses at the study clinic. The study consisted of 10 visits; One 2-part screening visit, 5 IMP administration visits, and 3 follow-up visits. Each individual patient's study participation was approximately 4 months, including the screening and follow-up visits.	
<b>Number of patients planned:</b>  15 patients	
<b>Objectives and endpoints</b>  <i>Primary objective:</i>  The primary objective of the study was to evaluate the safety and tolerability of ILB® in patients diagnosed with ALS.  <i>Primary endpoints:</i>  Frequency, seriousness and intensity of Treatment-emergent Adverse Events (TEAEs)  Physical examination  Vital signs  Electrocardiogram (ECG) recordings	

Safety laboratory measurements: clinical chemistry, haematology including activated partial thromboplastin time (APTT)

*Secondary objective:*

The secondary objective of the study was to evaluate efficacy of ILB® in patients diagnosed with ALS.

*Secondary endpoints:*

Functional rating with ALS Functional Rating Scale – Revised (ALSFRS-R)

Functional rating with Norris scale

Evaluation of ALS biomarker Neurofilament Light chain (NFL)

Evaluation of biomarkers for neurological disorders (see 11.4.2)

Pulmonary function (FVC)

Quality of Life (QoL)

Autonomous symptoms

Levels of Hepatocyte Growth Factor (HGF)

Pharmacokinetic measurements of ILB® in plasma

Changes in APTT (effect APTT)

*Exploratory objectives:*

To evaluate the effect of ILB® on levels of *e.g.* growth factors, cytokines and biomarkers in plasma and cerebrospinal fluid (CSF).

**Safety and efficacy assessments**

*Safety:*

AE assessments started at administration of the first dose of ILB®.

A physical exam was obtained at all visits. On the days of ILB® administration (Visit 2 to Visit 6), physical examination was obtained before dosing.

Vital signs (blood pressure, heart rate and body temperature) were obtained at all visits.

12-lead ECG were obtained at Visit 1 and Visit 7.

Lab tests (clinical chemistry, haematology, haemostasis) were obtained at all visits. On the days of ILB® administration (Visit 2 to Visit 6), lab tests were obtained before dosing.

*Efficacy:*

The clinical investigator completed the ALS Functional Rating Scale - Revised (ALSFRS-R) at all visits. On the days of ILB® administration, rating scales were completed before dosing.

The clinical investigator completed the Norris functional rating scales at all visits. On the days of ILB® administration, rating scales were completed before dosing.

Blood and cerebrospinal fluid (CSF) samples for evaluation of the ALS biomarker Neurofilament Light chain (NFL) were obtained at Visit 1 after eligibility was confirmed and at Visit 7.

Blood and CSF samples for analysis of biomarkers for neurological disorders were obtained at Visit 1 after eligibility is confirmed and at Visit 7.

Respiratory function (FVC) was evaluated at all visits. On the days of ILB® administration (Visit 2 to Visit 6), respiratory function was assessed before dosing.

Quality of Life (QoL) was evaluated using Visual Analogue Scale (VAS)-based questionnaire filled out by patient and, if applicable, a next of kin, at Visit 1, Visit 2, Visit 4, Visit 6 and Visit 8.

Autonomous symptoms were evaluated according to a 4-grade scale for a range of parameters at all visits.

Levels of Hepatocyte Growth Factor (HGF), pharmacokinetic measurements and effect APTT were obtained in conjunction with the first and last ILB® administration (Visit 2 and Visit 6). Blood samples were obtained pre-dose, 30 minutes and 1, 2, 2.5, 3, 4, 6 hours after dosing.

### **Eligibility criteria**

#### *Inclusion criteria:*

Willing and able to give written informed consent for participation in the study.

Clinical diagnosis of Amyotrophic Lateral Sclerosis.

Male or female patients between 18 to 80 years of age (inclusive).

Forced Vital Capacity (FVC)  $\geq$  65% of predicted value for gender, height and age at screening.

Evaluated with ALSFRS-R and Norris clinical rating scales for at least the past 4 weeks before study drug administration.

#### *Exclusion criteria:*

Unable to understand information about the study or are expected not to collaborate with the study team.

Concurrent serious disease, other than ALS, at the discretion of the Investigator.

Pregnancy.

Patients of child-bearing potential not willing to use adequate double contraception with < 1% failure rate after the screening visit until the last visit.

Addiction to drugs or alcohol.

Confirmed HIV, Hepatitis B or C.

Known bleeding disorders or abnormal bleeding events.

Treatment with anticoagulant drugs warfarin and novel oral anticoagulants (NOAC) within the last 14 days prior to screening.

Treatment with Riluzole or Lamotrigine within the last 28 days prior to study drug administration.

Hypersensitivity to dextran sulfate.

Poor venous access.

Patients with clinically significant abnormal PK-INR, fibrinogen, von Willebrand factor and activated partial thromboplastin time (APTT) at screening.

#### **Investigational Medicinal Product (IMP), dosage and mode of administration**

The active pharmaceutical ingredient of the IMP was a LMW-DS, named ILB®, that has a mean molecular weight of 5 kDa with 20% sulphation. ILB® is a unique and distinct LMW-DS formulation whose structure, formulation, synthesis and structure has been previously described in detail in a published patent document (publication number: WO 2016/076780 – New dextran sulphate). ILB® was provided by Tikomed AB in 10 mL vials containing a solution of 20 mg/mL ILB® in 9 mg/mL NaCl. A single batch of drug was used throughout the study (batch #8059701).

ILB® was injected subcutaneously on alternating sides of the abdomen. Five injections of 1 mg/kg, with a weekly dosing interval, were administered. The exact dose administered depended on the patient's body weight at Visit 2 (Day 1), prior to the first ILB® administration.

#### **Statistical methods**

No formal sample size calculation was performed for this study. The proposed sample size was considered sufficient in this early phase II development to provide adequate information on the patients.

Categorical data was presented as counts and percentages. Individual patient data was listed by subject number and, where applicable, assessment time.

Continuous data were summarised using descriptive statistics. The number of observations, mean, median, maximum, minimum and standard deviation were reported. Individual patient data was listed by subject number and, where applicable, assessment time.

Individual plasma concentration-time data of ILB® were evaluated using a validated Phoenix WinNonlin® software. The PK parameters were calculated by non-compartmental analysis (NCA). Descriptive statistics for the assessed PK parameters were presented for each parameter and first and last ILB® administration (Visit 2 and Visit 6), as well as pooled data over the dosing days (if appropriate).

A more technical and detailed elaboration of the principal features was presented in a separate Statistical Analysis Plan (SAP).



**Table S3.** Raw data reporting the circulating concentrations of citrulline (CITR), alanine (ALA), ornithine/citrulline ratio (ORN/CITR) detected in serum of each patient included in the study, before and after ILB® administration. Values are expressed as  $\mu\text{mol/l}$  serum. Significant differences on the Student's t-test for paired samples are marked in red. The concentrations of other amino acids and amino group-containing compounds (aspartate, glutamate, asparagine, serine, glutamine, histidine, glycine, threonine, arginine, taurine,  $\gamma$ -aminobutyrate, tyrosine, S-adenosylhomocysteine, L-cystathionine, valine, methionine, tryptophan, phenylalanine, isoleucine, leucine, ornithine, lysine) did not differ before and after treatment and were omitted from the Table for the sake of clarity.

PATIENT ID	CITR	ALA	ORN/CITR	PATIENT ID	CITR	ALA	ORN/CITR
TM - 105 SUBJ 101 EXPL SERUM B VISIT 1B	14.082	412.563	2.399	TM - 105 SUBJ 101 EXPL SERUM D VISIT 7	17.824	217.393	1.312
TM - 105 SUBJ 102 EXPL SERUM D VISIT 1B	32.910	428.911	1.312	TM - 105 SUBJ 102 EXPL SERUM D VISIT 7	14.863	416.915	1.859
TM - 105 SUBJ 103 EXPL SERUM A VISIT 1B	21.110	432.289	2.101	TM - 105 SUBJ 103 EXPL SERUM D VISIT 7	14.701	428.179	2.645
TM - 105 SUBJ 104 EXPL SERUM A VISIT 1B	21.239	484.059	1.854	TM - 105 SUBJ 104 EXPL SERUM A VISIT 7	17.852	429.757	1.228
TM - 105 SUBJ 105 EXPL SERUM B VISIT 1B	22.373	562.368	0.560	TM - 105 SUBJ 105 EXPL SERUM B VISIT 7	18.955	546.009	1.100
TM - 105 SUBJ 106 EXPL SERUM A VISIT 1B	18.152	403.358	0.523	TM - 105 SUBJ 106 EXPL SERUM D VISIT 7	13.831	328.553	2.235
TM - 105 SUBJ 107 EXPL SERUM A VISIT 1B	24.141	273.188	0.391	TM - 105 SUBJ 107 EXPL SERUM B VISIT 7	26.803	267.262	1.596
TM - 105 SUBJ 108 EXPL SERUM B VISIT 1B	38.921	466.325	1.249	TM - 105 SUBJ 108 EXPL SERUM D VISIT 7	29.179	315.148	1.490
TM - 105 SUBJ 109 EXPL SERUM A VISIT 1B	18.214	405.240	1.798	TM - 105 SUBJ 109 EXPL SERUM A VISIT 7	12.194	408.546	4.132
TM - 105 SUBJ 110 EXPL SERUM A VISIT 1B	22.540	346.071	1.908	TM - 105 SUBJ 110 EXPL SERUM D VISIT 7	22.693	374.396	1.626
TM - 105 SUBJ 111 EXPL SERUM A VISIT 1B	30.164	399.005	1.535	TM - 105 SUBJ 111 EXPL SERUM D VISIT 7	21.249	384.615	1.959
TM - 105 SUBJ 112 EXPL SERUM A VISIT 1B	26.660	598.715	1.777	TM - 105 SUBJ 112 EXPL SERUM D VISIT 7	14.447	417.786	4.043
TM - 105 SUBJ 113 EXPL SERUM B VISIT 1B	16.194	365.052	2.396	TM - 105 SUBJ 113 EXPL SERUM D VISIT 7	19.894	336.769	3.253
Mean	23.592	429.011	1.523	Mean	18.807	374.718	2.191
S.D.	7.028	85.956	0.683	S.D.	5.128	83.428	1.031
Two-tailed t-test for paired samples	0.021	0.022	0.037				

**Table S4.** Raw data reporting the circulating concentrations of the two main congeners of Vitamin E ( $\alpha$ -tocopherol and  $\gamma$ -tocopherol) detected in serum of each patient included in the study, before and after ILB® administration. Values are expressed as  $\mu\text{mol/l}$  serum. Significant differences on the Student's t-test for paired samples are marked in red. The concentrations of other fat-soluble vitamins and antioxidants (*all trans*-retinoic acid, *all trans*-retinol, coenzyme Q<sub>10</sub>, astaxanthin, phytoene, lutein, zeaxanthin, *trans*- $\beta$ -apo-8'-carotenal,  $\beta$ -cryptoxanthin, lycopene,  $\alpha$ -carotene,  $\beta$ -carotene, violaxanthin, 25-hydroxycholecalciferol) did not differ before and after treatment and were omitted from the Table for the sake of clarity.

PATIENT ID	$\alpha$ -tocopherol	$\gamma$ -tocopherol	PATIENT ID	$\alpha$ -tocopherol	$\gamma$ -tocopherol
TM - 105 SUBJ 101 EXPL SERUM B VISIT 1B	8.909	0.498	TM - 105 SUBJ 101 EXPL SERUM D VISIT 7	17.824	217.393
TM - 105 SUBJ 102 EXPL SERUM D VISIT 1B	6.419	0.640	TM - 105 SUBJ 102 EXPL SERUM D VISIT 7	14.863	416.915
TM - 105 SUBJ 103 EXPL SERUM A VISIT 1B	6.978	0.529	TM - 105 SUBJ 103 EXPL SERUM D VISIT 7	14.701	428.179
TM - 105 SUBJ 104 EXPL SERUM A VISIT 1B	7.314	0.297	TM - 105 SUBJ 104 EXPL SERUM A VISIT 7	17.852	429.757
TM - 105 SUBJ 105 EXPL SERUM B VISIT 1B	8.283	0.593	TM - 105 SUBJ 105 EXPL SERUM B VISIT 7	18.955	546.009
TM - 105 SUBJ 106 EXPL SERUM A VISIT 1B	6.137	0.410	TM - 105 SUBJ 106 EXPL SERUM D VISIT 7	13.831	328.553
TM - 105 SUBJ 107 EXPL SERUM A VISIT 1B	6.053	0.672	TM - 105 SUBJ 107 EXPL SERUM B VISIT 7	26.803	267.262
TM - 105 SUBJ 108 EXPL SERUM B VISIT 1B	3.504	0.400	TM - 105 SUBJ 108 EXPL SERUM D VISIT 7	29.179	315.148
TM - 105 SUBJ 109 EXPL SERUM A VISIT 1B	5.459	0.600	TM - 105 SUBJ 109 EXPL SERUM A VISIT 7	12.194	408.546
TM - 105 SUBJ 110 EXPL SERUM A VISIT 1B	8.528	0.417	TM - 105 SUBJ 110 EXPL SERUM D VISIT 7	22.693	374.396
TM - 105 SUBJ 111 EXPL SERUM A VISIT 1B	13.223	0.438	TM - 105 SUBJ 111 EXPL SERUM D VISIT 7	21.249	384.615
TM - 105 SUBJ 112 EXPL SERUM A VISIT 1B	23.568	0.268	TM - 105 SUBJ 112 EXPL SERUM D VISIT 7	14.447	417.786
TM - 105 SUBJ 113 EXPL SERUM B VISIT 1B	17.150	0.700	TM - 105 SUBJ 113 EXPL SERUM D VISIT 7	19.894	336.769
Mean	9.348	0.497	Mean	18.807	374.718
S.D.	5.544	0.139	S.D.	5.128	83.428
Two-tailed t-test for paired samples	0.037	0.028			

**Table S5.** Raw data reporting the circulating concentrations in serum of heathy controls of those metabolites affected by ILB treatment in patients with ALS. Values are expressed as  $\mu\text{mol/l}$  serum. Means and S.D. are indicated at the end of each column and marked in red.

HEALTHY CONTROLS	URIC ACID	MDA	NAA	SUM OXYPURINES	NO2 + NO3	CTR	ALA	ORN	ORN/CTR	$\alpha$ -tocopherol	$\gamma$ -tocopherol
1	281.680	0.026	0.077	286.180	26.360	25.215	468.360	58.240	2.310	22.480	0.498
2	193.380	0.018	0.013	198.630	42.940	14.640	340.080	64.747	4.423	25.660	1.291
3	178.800	0.026	0.054	188.750	29.740	14.040	199.800	32.427	2.310	17.810	1.009
4	227.080	0.080	0.080	233.420	15.980	20.670	321.480	102.400	4.954	31.020	1.480
5	280.530	0.024	0.043	285.950	33.020	15.925	357.840	100.213	6.333	19.590	1.288
6	350.900	0.028	0.021	362.660	33.770	20.370	396.880	91.200	4.477	24.550	1.233
7	276.900	0.014	0.027	282.210	17.890	19.875	366.720	63.387	3.491	16.900	1.080
8	348.890	0.054	0.024	357.360	45.520	21.960	417.120	86.827	3.954	33.310	0.980
9	246.410	0.029	0.067	252.580	35.720	21.765	292.440	88.240	4.514	19.150	1.350
10	309.330	0.009	0.032	319.710	35.200	22.095	272.760	64.653	2.899	18.490	1.280
11	250.720	0.078	0.054	258.480	33.710	25.000	431.640	157.893	6.316	24.450	0.749
12	345.110	0.080	0.028	348.620	30.090	19.875	289.220	67.520	3.397	22.240	0.980
13	359.940	0.011	0.094	370.360	48.830	19.600	227.760	138.187	7.077	27.090	1.560
14	301.060	0.009	0.049	309.400	31.650	23.445	311.520	81.120	3.460	25.370	1.330
15	380.900	0.020	0.016	389.170	35.680	19.980	340.240	36.880	1.846	27.760	1.490
16	269.700	0.038	0.016	265.530	14.680	15.000	314.400	125.153	8.344	28.110	1.640
17	292.360	0.033	0.058	300.510	32.860	19.875	440.400	131.893	6.636	29.420	1.310
18	182.050	0.056	0.016	186.680	269.120	81.320	4.418			22.550	0.940
19	317.640	0.004	0.035	326.415	38.660	23.445	344.760	84.327	3.597	20.760	1.460
20	320.470	0.035	0.015	328.890	18.990	19.980	470.000	63.467	3.275	16.560	0.770
21	181.010	0.019	0.055	186.520	17.860	12.640	368.800	100.453	4.435	7.120	0.920
22	307.040	0.038	0.051	313.930	39.800	23.235	273.840	94.907	4.085	20.520	0.800
23	291.560	0.037	0.040	295.640	20.870	22.350	301.170	97.400	4.358	30.120	1.030
24	239.170	0.060	0.025	243.240	34.470	15.435	495.960	43.687	2.830	24.240	1.100
25	276.890	0.006	0.021	287.400	22.950	16.000	438.960	52.160	3.260	24.600	0.720
26	331.970	0.047	0.045	339.390	47.490	23.040	356.440	44.693	1.940	27.520	0.690
27	267.030	0.033	0.106	271.115	16.000	495.120	66.417	3.528	17.680	1.840	0.841
28	297.960	0.011	0.041	304.400	20.610	15.330	366.600	116.800	7.619	21.720	0.960
29	336.400	0.032	0.026	344.490	32.890	28.875	489.320	43.327	1.500	26.160	1.130
30	224.000	0.099	0.235	233.030	12.690	12.990	392.520	79.000	4.246	13.200	1.400
31	173.780	0.023	0.070	187.020	52.990	20.175	428.400	80.447	3.987	29.880	0.950
32	182.410	0.002	0.079	195.340	49.230	19.380	459.000	63.467	3.275	24.240	1.280
33	366.420	0.060	0.017	378.620	62.560	19.185	390.080	48.653	2.536	26.600	0.960
34	300.360	0.052	0.043	305.100	36.870	12.765	268.760	58.947	4.481	23.200	1.510
35	175.360	0.033	0.023	186.840	26.980	12.000	377.160	49.553	4.129	24.360	0.910
36	288.660	0.106	0.014	293.810	20.920	17.700	324.360	135.907	7.678	23.280	0.870
37	334.490	0.023	0.042	343.510	33.250	21.960	384.360	66.280	3.018	30.000	1.250
38	324.020	0.080	0.160	332.400	12.240	14.445	397.400	28.340	1.963	21.680	0.943
39	259.230	0.020	0.014	276.720	15.180	25.515	393.000	62.227	3.658	24.960	1.080
40	231.190	0.019	0.018	239.120	26.360	26.265	433.080	111.487	4.245	27.240	1.190
41	239.650	0.056	0.138	252.580	337.100	212.760	248.040	41.720	1.961	29.770	1.320
42	365.280	0.013	0.021	371.160	26.370	21.960	466.080	112.113	5.105	29.520	1.750
43	382.430	0.038	0.011	403.440	15.520	15.330	480.480	88.247	5.756	29.640	1.570
44	285.020	0.056	0.022	303.880	17.660	15.330	523.200	71.680	4.493	25.200	1.200
45	251.340	0.012	0.009	257.430	13.910	12.060	342.360	72.673	6.026	28.680	1.020
46	265.660	0.021	0.007	275.620	26.830	16.040	443.160	113.013	7.046	25.440	0.880
47	265.660	0.046	0.014	278.130	19.170	22.655	291.600	16.000	4.278	24.440	0.950
48	184.830	0.009	0.019	190.990	27.700	19.050	350.520	118.800	6.236	28.800	0.790
49	365.700	0.012	0.010	373.000	24.600	16.090	259.320	110.400	5.907	32.880	1.110
50	268.660	0.043	0.002	275.910	27.790	23.225	269.520	87.520	3.794	26.120	1.240
51	364.330	0.050	0.014	373.540	26.790	14.040	372.720	129.280	9.208	24.360	0.910
52	222.440	0.047	0.008	227.440	37.200	19.312	256.480	114.193	5.913	30.360	0.910
53	336.620	0.034	0.013	339.960	32.180	16.680	299.480	73.687	4.432	27.600	1.460
54	386.460	0.004	0.013	392.470	25.190	20.637	266.436	105.107	5.093	28.800	0.740
55	170.510	0.027	0.008	175.330	29.620	18.513	289.680	21.013	1.135	21.680	0.880
56	289.010	0.037	0.034	293.810	30.980	14.795	268.720	63.653	6.091	23.160	0.960
57	278.840	0.007	0.012	285.670	26.920	18.440	248.160	101.440	5.501	23.280	1.150
58	257.460	0.008	0.012	262.720	29.590	19.529	397.760	123.413	6.919	25.520	0.920
59	136.110	0.036	0.009	141.470	19.990	17.770	377.120	85.600	4.660	26.670	0.675
60	320.560	0.026	0.012	328.830	37.520	18.077	517.120	129.093	7.141	27.820	1.320
61	181.010	0.049	0.016	186.420	242.810	142.800	187.887	4.611		27.460	0.640
62	224.710	0.031	0.023	239.790	27.210	15.173	332.100	92.240	6.079	30.360	1.130
63	365.090	0.047	0.010	373.600	30.230	11.616	322.720	53.831	4.634	18.840	1.740
64	293.110	0.031	0.044	299.000	34.570	17.465	264.480	112.607	5.640	25.120	0.960
65	169.690	0.009	0.032	171.770	29.030	14.956	451.100	78.720	5.264	17.880	0.920
66	325.000	0.015	0.018	335.970	42.880	24.600	375.160	147.733	6.005	18.120	0.780
67	291.010	0.013	0.033	304.940	13.840	18.117	348.640	55.240	2.186	26.160	1.030
68	406.440	0.034	0.022	415.430	38.800	15.972	296.960	134.713	8.434	18.240	1.120
69	238.230	0.019	0.017	243.420	18.250	16.214	554.240	105.767	6.523	28.800	0.720
70	221.880	0.064	0.018	231.190	23.820	20.370	300.320	71.547	3.478	23.680	0.980
71	296.400	0.033	0.016	305.390	30.620	18.513	285.400	78.973	4.266	22.320	0.830
72	332.710	0.045	0.018	344.960	35.540	14.933	470.480	104.513	8.533	33.240	0.960
73	237.210	0.014	0.018	243.740	28.840	20.655	302.480	47.273	1.877	22.440	1.130
74	289.290	0.030	0.017	294.440	27.590	17.206	431.120	51.273	2.980	25.540	1.400
75	339.330	0.029	0.015	342.830	33.160	14.665	589.520	89.753	4.778	37.470	0.950
76	275.860	0.027	0.017	279.100	22.920	22.088	361.040	84.973	3.772	27.680	0.940
77	207.450	0.039	0.029	216.190	24.140	16.625	406.000	103.987	6.201	25.960	0.990
78	307.280	0.018	0.017	316.170	17.890	20.618	476.160	139.287	6.955	26.910	1.510
79	382.640	0.089	0.018	388.580	21.440	17.061	502.880	78.847	4.521	29.910	1.010
80	254.440	0.077	0.028	261.320	27.940	16.408	449.600	90.733	5.530	29.450	0.870
81	261.620	0.075	0.026	269.230	13.960	16.420	395.600	175.000	9.223	27.820	1.260
82	268.260	0.125	0.017	271.105	23.180	19.965	203.272	126.453	6.334	29.360	1.130
83	289.760	0.103	0.018	295.720	24.440	16.916	388.264	87.133	5.151	29.900	1.080
84	252.790	0.111	0.016	262.140	20.760	20.643	295.096	152.673	5.991	21.610	1.190
85	301.240	0.093	0.030	304.950	45.640	18.005	408.356	103.440	5.745	28.790	1.330
86	257.320	0.133	0.015	262.600	88.850	21.199	484.856	131.200	6.189	29.890	1.760
87	274.670	0.151	0.019	283.100	34.300	13.034	555.420	79.453	5.887	28.800	1.030
88	306.620	0.088	0.013	312.740	26.340	24.810	429.054	113.920	4.592	17.070	0.790
89	291.870	0.101	0.019	296.180	33.870	20.869	333.640	109.547	5.252	27.170	1.220
90	269.660	0.122	0.016	285.210	27.470	14.884	164.176	55.717	3.955	19.950	0.910
91	225.540	0.145	0.026	229.790	29.170	9.365	241.380	34.427	3.676	26.560	1.320
92	251.010	0.078	0.016	257.710	47.260	18.440	237.340	63.093	5.648	34.040	0.762
93	234.620	0.161	0.011	245.910	11.660	19.995	363.808				